CCI Antibody

Recombinant Viral CCI Fc Chimera (Catalog # 696‑CC) inhibits Recombinant Mouse CCL2/JE (Catalog # 479‑JE) induced chemotaxis in the BaF3 mouse pro‑B cell line transfected with human CCR2A in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (Catalog # AR002). Inhibition of Recombinant Mouse CCL2/JE (20 ng/mL) activity elicited by Recombinant Viral CCI Fc Chimera (0.4 µg/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Viral CCI Antigen Affinity-purified Polyclonal Antibody (Catalog # AF696). The ND50 is typically 3-15 µg/mL.

• Reactivity: V
• Applications: WB, B/N
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Unconjugated
• Concentration: LYOPH

CCI Antibody Summary

• Immunogen: S. frugiperda insect ovarian cell line Sf 21-derived recombinant viral CCI
• Specificity: Detects viral CCI in direct ELISAs and Western blots.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Purity Statement: Antigen Affinity-purified
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • Neutralization 3-15 ug/mL
  • Western Blot 0.1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for CCI Antibody

• CCI

Background

The family of T1/35 kDa proteins are secreted, soluble proteins encoded by the '35K' virulence gene of many poxviruses. These proteins have been shown to bind CC-chemokines with high affinity and are now termed viral chemokine inhibitor (vCCI). Viral CCI from various poxviruses share multiple stretches of identical sequence motif and eight conserved cysteine residues. The vaccinia virus (strain Lister) vCCI cDNA encodes a 258 amino acid (aa) residue protein with a putative 17 amino acid residue signal peptide. Vaccinia virus (strain Lister) vCCI shows greater than 90% aa sequence identity with vCCI from other orthopoxviruses and approximately 40% aa sequence identity with the leporipoxvirus T-1 proteins.

Recombinant vCCI has been shown to be a potent general inhibitor of CC-chemokine activity in vitro and blocks binding of CC chemokines to cell surface chemokine receptors. In in vivo studies using a virus mutant in which the gene encoding the CCI has been deleted, leukocyte infiltration into the virus-infected areas is increased, suggesting that CCI can modulate the influx of inflammatory cells into virus-infected tissues.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.